ArticleRespiratory medicine2021
Bronchodilator reversibility testing in post-COVID-19 patients undergoing pulmonary rehabilitation.
Article in Respiratory medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05770440 (Impact of COVID-19 on Lung Function in COPD Patients), which is not on this map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Impact of COVID-19 on Lung Function in COPD Patients
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- A Series of Severe and Critical COVID-19 Cases in Hospitalized, Unvaccinated Children: Clinical Findings and Hospital Care.Epidemiologia (Basel, Switzerland) · 2025Article
- Changes in Respiratory Sensitivity Status of Patients in a Hospital in Shanxi Province Before and After the COVID-19 Epidemic.Journal of asthma and allergy · 2025Article
- FOT Technique Applied for Monitoring of COVID-19 Pneumonia Reveals Small Airways Involvement.Diagnostics (Basel, Switzerland) · 2024Article
- Review
- Synergistic effects of COVID-19 and Pseudomonas aeruginosa in chronic obstructive pulmonary disease: a polymicrobial perspective.Molecular and cellular biochemistry · 2024Review
- Bronchodilator Response in Post-COVID-19 Patients Undergoing Pulmonary Rehabilitation.Respiration; international review of thoracic diseases · 2024Article
- Small airway disease in post-acute COVID-19 syndrome, a non-conventional approach in three years follow-up of a patient with long COVID: a case report.Journal of medical case reports · 2023Article
- Implementing a Multidisciplinary Post-COVID Clinic in a Small Community Environment.Archives of rehabilitation research and clinical translation · 2023Article
- One stone two birds: anti-inflammatory bronchodilators as a potential pharmacological strategy for COVID-19.Frontiers in pharmacology · 2023Review
- The Hidden Pandemic of COVID-19-Induced Organizing Pneumonia.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Bronchodilator Response as a Possible Predictor of Lung Function Improvement After Pulmonary Rehabilitation in Post-COVID-19 Patients.Archivos de bronconeumologia · 2022Article
- Can FeNO be a biomarker in the post-COVID-19 patients monitoring?Respiratory medicine · 2022Article
- The Disease-Modifying Role of Taurine and Its Therapeutic Potential in Coronavirus Disease 2019 (COVID-19).Advances in experimental medicine and biology · 2022Review
- Noncommunicable diseases, climate change and iniquities: What COVID-19 has taught us about syndemic.European journal of clinical investigation · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe usefulness of bronchodilators in coronavirus diseases 2019 (COVID-19) survivors is still uncertain, especially for patients with a concomitant obstructive lung disease. We aimed at verifying the level of bronchodilator reversibility in COVID-19 patients undergoing multidisciplinary pulmonary rehabilitation after the acute phase.
methodsWe enrolled 105 consecutive patients referring to the Pulmonary Rehabilitation Unit of Istituti Clinici Scientifici Maugeri Spa SB, IRCCS of Telese Terme, Benevento, Italy after being discharged from the COVID-19 acute care ward and after recovering from acute COVID-19 pneumonia. All subjects performed a spirometry before and after inhalation of salbutamol 400 μg to determine the bronchodilation response within 48 h of admission to the unit.
resultsAll patients had suffered from a moderate to severe COVID-19, classified 3 or 4 according to the WHO classification, Seventeen patients had concomitant obstructive lung disease (14 suffering from COPD and 3 from asthma). FEV
conclusionsThis study suggests that a treatment with bronchodilators must always be taken into consideration in post-COVID-19 patients because it can induce a functional improvement that, even if small, can facilitate the breathing of these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.